HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US EPA Should Eliminate ‘Hazardous’ Chemicals In Cosmetics? Petition Denied

Executive Summary

The Environmental Protection Agency does not have the jurisdiction to grant William D. Bush’s request, even if the petitioner had specified the “chemical mixtures” he wants banned or provided the level of data required to initiate proceedings under the Toxic Substances Control Act.

You may also be interested in...



EU’s Planned Revision Of Cosmetics Regulation Makes For Uneasy Global Industry

To cosmetics industry stakeholders, the EU’s talk of instituting a generic risk management approach to eliminate “most hazardous” chemicals spells wholesale adoption of the precautionary principle, the disposal of exposure and risk considerations, and, ultimately, increased cosmetic ingredient restrictions and bans without proportionate human health benefits.

Four Federal Cosmetics Bills On Cusp Of Introduction

Ostensibly taking cues from California and lessons from previous congressional sessions, US lawmakers, NGOs and “forward-thinking cosmetics companies” seek piecemeal cosmetics reform via four federal bills slated for introduction in the coming week.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel